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Abstract: The first description of the Reeler mutation in mouse dates to more than fifty years
ago, and later, its causative gene (reln) was discovered in mouse, and its human orthologue
(RELN) was demonstrated to be causative of lissencephaly 2 (LIS2) and about 20% of the cases of
autosomal-dominant lateral temporal epilepsy (ADLTE). In both human and mice, the gene encodes for
a glycoprotein referred to as reelin (Reln) that plays a primary function in neuronal migration during
development and synaptic stabilization in adulthood. Besides LIS2 and ADLTE, RELN and/or other
genes coding for the proteins of the Reln intracellular cascade have been associated substantially to
other conditions such as spinocerebellar ataxia type 7 and 37, VLDLR-associated cerebellar hypoplasia,
PAFAH1B1-associated lissencephaly, autism, and schizophrenia. According to their modalities of
inheritances and with significant differences among each other, these neuropsychiatric disorders
can be modeled in the homozygous (reln−/−) or heterozygous (reln+/−) Reeler mouse. The worth
of these mice as translational models is discussed, with focus on their construct and face validity.
Description of face validity, i.e., the resemblance of phenotypes between the two species, centers onto
the histological, neurochemical, and functional observations in the cerebral cortex, hippocampus,
and cerebellum of Reeler mice and their human counterparts.
Keywords: reelin; LIS2; ADLTE; autism; schizophrenia; translational models; GABAergic
interneurons; dendritic spines; forebrain; cerebellum
1. Introduction
Neuronal migration and precise setting during neurogenesis depend, among others, on reelin
(Reln), a 388 kDa glycoprotein secreted by certain neurons within the extracellular matrix [1,2].
The name was given to the protein after the detection of its coding gene, and the acknowledgement
that its lack was causative of the mouse Reeler mutation [3], which was described, about half a century
before, consisting in a form of ataxia [4]. The mutation is autosomic and shows recessive transmission.
Consequently, only homozygous recessive Reeler mice (reln−/−) are totally devoid of Reln and have
a definite phenotype. Behaviorally, the latter consists of dystonia, ataxia, and tremor; structurally it
primarily affects the design of the cerebral cortex, hippocampus, and cerebellum [5,6]. Contrarily to
the mutants, the phenotype of heterozygous Reeler mice (reln+/−) is normal, but, interestingly, these
animals may be translational models of certain human neuropsychiatric disorders [7].
Shortly after the original discovery, it became clear that the mouse gene (reln) had a very high
homology to that in humans (RELN) [8]. Then, a few years later, it was shown that autosomic recessive
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mutations of the RELN gene were linked to a form of lissencephaly with cerebellar hypoplasia (LCH) [9],
with associated findings suggested that RELN was linked to some neuropsychiatric conditions [10],
and RELN was demonstrated to be reduced in the cerebellum of autistic patients after Western blotting
and immunodetection [11].
Determining a good translational mouse model for a neuropsychiatric condition needs construct,
predictive, and face validity [12]. Rigorously, construct validity only relates to transgenic mice,
but, in a broader definition, it also comprehends the syndromic models and the spontaneous DNA
mutations linked to the phenotype under study. In other words, this factor defines the similarity of the
disease between the mouse and the human disorder in terms of the causal gene(s) as e.g., deducted
from gene association and linkage analysis. As mentioned above, LCH is a human monogenic
condition caused by a mutation in RELN. Therefore, the Reeler mouse fully meets the criterion of
construct validity for the condition. There is also evidence for genetics to be associated with the
etiology of several neuropsychiatric conditions, such as autism and schizophrenia, but, as the result
of their multidimensional clinical symptoms, causal gene(s), if any, persist to be undiscovered [13].
Nonetheless, there are numerous genes associated with the human autistic pathology after analysis of
Mendelian disorders (syndromes), rare mutations, or association studies; see e.g., [14].
Predictive validity, i.e., the similarity of the response to cures in humans and mice is difficult
to establish, in the nonexistence of a recognized therapy in humans [14]. Thus, in the context of this
discussion, face validity, i.e., the resemblance of the model phenotype to that of the human disorder,
is the most important parameter to consider.
Assessment of face validity in neuroscience translational studies requires a careful consideration
of their behavioral and structural phenotypes. Broadly speaking, there are contradictory opinions
as regarding the repetition in mouse of the human behavioral neuropsychiatric changes. This was,
to some extent, predictable, as only a few trials, such as e.g., pre-pulse inhibition (PPI), which
records sensory-motor responses, are highly comparable with only minimal modifications in the two
species [15]. Notably, the issue has been the subject of several reviews on rodent models of autism,
e.g., [16]. The conclusion of these surveys was that, although most of the models that have been used
in drug discovery display behaviors with face validity for the human symptoms (i.e., deficits in social
communication and restricted interests/repetitive behaviors), many drugs that were found to be useful
in ameliorating these autism-related behaviors in mice were ineffective in humans.
Therefore, it becomes imperative to compare the structural alterations of the brains in the two
species to substantiate or invalidate the models. We here summarize the state-of-art knowledge on the
translational validity of homozygous (reln−/−) and heterozygous (reln+/−) Reeler mice with reference to
the most common neuropsychiatric conditions directly or indirectly related to RELN. Because of its
importance, we will primarily focus onto the brain structural modifications at magnetic resonance
imaging (MRI) and histopathology in the two species.
2. The Reelin Gene and Protein
In humans, RELN, which has 94.2% homology with the mouse orthologue [8], is in chromosome
7q22 [17] and encodes for REELIN (RELN), a large glycoprotein of the extracellular matrix. The murine
gene (reln) that also encodes for Reelin (Reln) was originally identified as the mutated gene in the Reeler
mouse, which displays, among others, irregular lamination of the cerebral and cerebellar cortices, with
an inversion of the regular ‘inside-out’ design observed in mammals [3,18]. The mouse and the human
proteins have a similar size of 388 kDa. The structure of the protein recalls that of certain cell adhesion
molecules, which specific cell types produce during brain and spinal cord development.
In the neocortex, the Cajal–Retzius cells synthesize the glycoprotein and secrete it into the
extracellular space [19]. Then, in post mitotic migrating neurons, Reln activates a specific signaling
pathway that is required for proper positioning of these neurons. Northern blot hybridization showed
that other areas of the fetal and postnatal brain also express the protein, with levels particularly high
in cerebellum.
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Reln is part of a signal transduction pathway that includes the apolipoprotein E2 (ApoER2), the very
low-density lipoprotein receptors (VLDLR) and the cytoplasmic protein Dab1 [20]. Notably, the brain
phenotype of mice with disruptions of mDab1 or of both apoER2 and vldlr closely resemble the brain of
the Reeler mouse [21]. Another gene that interacts with the components of the Reln signaling pathways
is platelet-activating factor acetyl hydrolase IB subunit α (PAFAH1B1), also referred to as LIS1 [22].
3. RELN-Related Human Neurological Conditions and Their Mouse Counterparts
Several human neurological conditions have a direct or indirect link with RELN and its encoded
protein, as well as with the components of the RELN signaling pathway (Figure 1 and Table 1). We will
briefly describe these conditions below, aiming to put in the better perspective those features that may
be useful for well understanding the translational relevance of the Reeler mouse.
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Table 1. Summary list of the human neurological conditions related to the RELN gene.
Disease Transmission Causative Gene(s) Reeler Mutants ofTranslational Interest
Other Mouse
Models
LIS 2 Autosomal recessive RELN Homozygous see text
ADLTE Autosomal dominant RELN(in 17.5% of cases) Heterozygous LG11-mutated
VLDLR-associated
cerebellar hypoplasia Autosomal recessive VLDLR Homozygous VLDLR knock-out
SCA37 Autosomal dominant DAB1 Homozygous DAB1 knock-outapoER2 knock-out
PAFAH1B1-associated
lissencephaly Autosomal dominant PAFAH1B1 Homozygous Lis1
+/−
SCA7 Autosomal dominant ATXN7 Homozygous SCA7 knock-in
Autism Isolated casesMultifactorial see https://omim.org # 209850 Heterozygous see text
Schizophrenia Autosomal dominant see https://omim.org # 181500 Heterozygous see text
Note that only LIS2 and autosomal-dominant lateral temporal epilepsy (ADLTE) have a demonstrated link with
RELN. RELN may be relevant for LIS1.
3.1. Neurological Conditions Caused by RELN Mutations
Several diseases are based on mutations of RELN or of genes encoding for proteins associated with
the RELN signaling pathways. Among these, lissencephaly 2 (LIS2) and autosomal-dominant lateral
temporal epilepsy (ADLTE) are of relevance to the present discussion as they have a clear genetic link
with RELN.
3.1.1. Human Lissencephalies and the Homozygous Reeler Mouse
Human lissencephalies are a group of cortical malformations that are consequent to neuronal
migration disorders. Broadly speaking, the structural phenotype in lissencephalies ranges from a
thickened cortex and complete absence of sulci (agyria) to a thickened cortex with a few, shallow
sulci (pachygyria) [23]. The main feature of classic lissencephaly, formerly referred to as type I
lissencephaly but today named lissencephaly 1 (LIS1), is a marked thickening of the cerebral cortex
with a posterior to anterior grade of severity. An anomalous neuronal migration in the interval between
the ninth to the thirteenth week of pregnancy causes LIS1, resulting in an assortment of agyria, mixed
agyria/pachygyria, and pachygyria. An abnormally thick and ill ordered cortex with four highly
disorganized layers, diffuse neuronal heterotopia, enlarged cerebral ventricles of anomalous shape, and,
often, hypoplasia of the corpus callosum are typical of LIS1 [24]. The basal ganglia are normal, except
that the anterior limb of the internal capsule is usually not noticeable, and, most often, the cerebellum
is normal as well.
Lissencephalies are now classified based on brain imaging results and molecular investigation [25],
as they have been associated with mutations in several genes such as LIS1 (PAFAH1B1; MIM#601545),
DCX (Doublecortin; MIM#300121), ARX (Aristaless-related homeobox gene; MIM#300382), RELN
(Reelin; MIM#600514), VLDLR (MIM#224050) and TUBA1A (αtubulin 1a) [26]. Some rare forms of
lissencephaly (LCH) are associated with a disproportionately small cerebellum.
Lissencephaly 2
a) Humans
Lissencephaly 2 (LIS2) also referred to lissencephaly syndrome, Norman–Roberts type or
Norman–Roberts syndrome (OMIM #257320) is associated with LIS1 but displays several specific
clinical features. In 2000, Hong and colleagues were the first to describe an autosomal recessive
form of lissencephaly that, at MRI, also exhibited severe alterations of the cerebellum, hippocampus,
and brainstem. More specifically, these alterations consisted of a thickening of the cerebral cortex with a
simplified convolutional pattern that was particularly evident in the frontal and temporal lobes, whereas
the parietal and occipital lobes were almost normal. The hippocampus was unfolded and flattened,
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lacking definable upper and lower blades. The corpus callosum was thin and the lateral ventricles
enlarged. The cerebellum was clearly smaller than in the normal brain, hypoplastic, and devoid of folia.
Authors also showed that the responsible gene mapped to chromosome 7q22 and that the condition
was associated with two independent mutations in RELN, resulting in low or undetectable amounts of
RELN after Western blots analysis of the patients’ serum [9]. Two other unrelated groups of patients,
later, presented the same type of LIS2 [27]. They were children that, at MRI, displayed a 5–10 mm thick
cerebral cortex, a malformed hippocampus and a very hypoplastic cerebellum, almost completely
devoid of folia. As LIS2 is a rare disease, there are very limited histopathological data on the condition.
To our knowledge, the only post-mortem description of a male fetus with Norman–Roberts syndrome
reported the occurrence of a four-layered cerebral cortex (Figure 2A,B), a well-developed cerebellum
with organized folia, and heterotopia of the dentate nucleus [28].
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Figure 2. Structural alterations in human, LIS2, and ho ozygous Reeler ouse ( – ); odifications of
the neocortex architecture in human LIS2 (B); and Reeler mutation (D); compared to healthy controls
(A,C). After MRI imaging, the human LIS2 cortex is thicker than normal, whereas there are apparently
no thickness changes in mouse. Note that in both species the pathological neocortex only consists of
four layers, with an upside-down layer disposition mainly affecting the pyramidal neurons that are also
irregularly oriented compared to their usual positioning in normal individuals/mice. Pyramidal neurons
are in different color and sizes according to their position in cortical layers. Stellate spiny cells of layer
4 are orange. Inhibitory interneurons are black with a red nucleus. Cajal-Retzius cells of layer 1 are red.
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(E–H): Structural alterations in the Reeler mouse cerebellum; (E) sagittal sections of the P15 cerebellum
in a normal reln+/+ mouse; and (F) a Reeler reln−/− mouse: the Reeler cerebellum is much smaller and
devoid of folia, with a smooth surface. (G) Misalignment of the Purkinje neurons in the P60 cerebellum
of the Reeler mouse. After calbindin 28 kDa immunostaining, the Purkinje neurons are well aligned in a
monolayer below the molecular layer in reln+/+ mice. They, instead, form a large internal cellular mass
within the white matter in reln−/− mutants (H). Abbreviations: DAPI = 4′,6-Diamidine-2′-phenylindole;
GL = granular layer of the cerebellar cortex; ICM = internal cellular mass; ML = molecular layer of the
cerebellar cortex; P = postnatal day.
b) Reeler Homozygous Mice
Alterations in Reeler homozygous recessive mice fully recapitulate those in human LIS2 (Figure 1).
Due to obvious technical and practical reasons, the amount of MRI data in mouse is by far less abundant
than in patients, whereas mice have provided extensive histopathological information. The first
MRI description of the neuroanatomical phenotypes in homozygous (and heterozygous) mice using
morphometry and texture analysis, led to conclude that the structural features of the Reeler brain
most closely copied the MRI phenotype of LIS2 patients [29]. Indeed, the reln−/− mice had a smaller
brain, but larger lateral ventricles compared to wild-type littermates. Sharp differences existed in the
olfactory bulbs, dorsomedial frontal and parietal cortex, certain districts of the temporal and occipital
lobes, and the ventral hippocampus where gadolinium-based active staining demonstrated a general
disorganization with differences in the thickness of individual hippocampal layers. The cerebellum also
resulted profoundly affected by the mutation and appeared strongly hypoplastic. A subsequent study,
based on the use of manganese-enhanced MRI (MEMRI) to better detect the cortical laminar architecture,
compared the MEMRI signal intensity in the cerebral cortex of normal and mutant mice. The authors of
this survey observed that signal was low in cortical layer 1, increased in layer 2, decreased in layer 3 until
mid-layer 4, and increased again, peaking in layer 5, before decreasing through layer 6. In Reeler there
were, instead, no appreciable changes in signal intensity, an observation consistent with the absence
of cortical lamination after histological examination [30]. A more recent and very elegant study has
employed diffusion tractography imaging (DTI) to perform an in vivo origin-to-ending reconstruction
of the mouse somatosensory thalamo-cortical connections and demonstrated an extensive remodeling
in Reeler mutants because of the highly disorganized cortical lamination [31].
In keeping with the results of imaging studies, at gross anatomical examination the reln−/− mouse
brain was atrophic, as total volume in mutants decreased of about 19% when compared to normal
mice [29]. Such a reduction was particularly evident in the cerebellum (Figure 2E,F) that also displayed
a very limited degree of foliation. Therefore, also the gross anatomy of the Reeler brain closely resembled
that of the LIS2 human brain.
In general, it seems that the histological anomalies in mutants depended on an abnormal migration
of neurons, rather than an alteration in cell fate determination or axonal guidance. Among these
anomalies, the most distinguishing ones are that the cerebral and cerebellar cortices lose their layered
structure, in accordance with the MEMRI observations [30]; numerous neuronal nuclei disappeared
or, at least, became hardly recognizable in several brain regions; and neurons often displayed an
ectopic position. Table 2 summarizes the most important structural anomalies of the reln−/− CNS
without taking into consideration the histological alterations in the cerebral cortex, hippocampus and
cerebellum, as we will analytically discuss the phenotype of these brain areas in the following sections.
Detailed descriptions of the morphological phenotype of the Reeler mouse CNS can be found e.g.,
in [29,32].
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Table 2. Main histopathological changes in the homozygous Reeler mouse.
Division of CNS Region/Division Subdivision/Nucleus Type(s) of Alteration Ref
Forebrain
Olfactory bulb
• Slight disruption of the
glomerular layer.
• Numerical reduction and
clustering of granule cells
[33,34]
Striatum • Decreased PV-immunoreactivity [35]
Diencephalon
• Misrouting of GnRH neurons to
the cerebral cortex [36]
Mammilary bodies
• Alteration of projections
to hippocampus [37]
Midbrain
Rostral colliculus
• Loss of individual limits in the
three more superficial layers
• Spread of
corticotectal projections
• Anomalies of
retinotectal projections
[38]
Mesencephalic
nucleus of V
• Spread of neurons along their
route of migration [39]
Substantia nigra
• Anomalous clustering lateral to
the ventral tegmental area [40]
Medulla
oblongata and
pons
Dorsal cochlear nucleus
• Partial loss of
layered organization [41]
Inferior olivary nucleus • Loss of folding - Swelling [42]
Somatic motorneurons
(Nucleus ambiguous, facial
and trigeminal)
• Slight displacement and loss of
somatotopic organization
(muscolotopy)
[6,43]
Pontine nuclei • Ventral shift [44]
Spinal cord
Dorsal horn
(laminae I-II) Nociceptive
• Abnormal neuronal positioning [45]
Lateral horn Preganglionic sympatheticand parasympathetic neurons
• Abnormal neuronal positioning [46,47]
The Table does not list the histopathological observations on cerebral cortex, hippocampus, and cerebellum.
Very early observations demonstrated the occurrence of dendritic anomalies in cortical and
hippocampal neurons of Reeler mice [48,49]. The discovery of Reln confirmed the dendritic pathology,
as not only Reln but also the molecules of its signaling pathway resulted to be necessary for the correct
maturation and differentiation of the dendritic branches and spines in hippocampal and neocortical
pyramidal neurons [50,51].
Due to the complexity of the phenomena involved in dendritic maturation, one can argue that
dendritic anomalies represented a consequence of the deep cytoarchitectonic derangement occurring
in Reeler mice rather than a primary effect of the lack of Reln, but observations on heterozygous mice
were not supportive of this interpretation [52,53]. Interestingly, the block of the Reln signaling by
means of specific antibodies resulted in an increased complexity of branching in the apical dendrites of
layer 2/3 cortical pyramidal neurons, whereas their basal arborizations remained unaffected [54].
There are many important issues related to the structure and role of the dendritic tree of neocortical
and hippocampal pyramidal neurons that make the Reeler mouse an important tool for the study of
(forebrain) neurodevelopment. Inputs to layer 5 neurons are processed by separate compartments,
with the basal dendrites receiving bottom-up information and the apical dendrite being the recipient
of a feedback input from higher cortical areas, see e.g., [55]. This framework is, however, even more
complex because apical dendrites span most cortical layers before reaching layer 1, where the apical tuft
is located [56]. Today we know well that the type and distribution of ion channels at the neurolemma
ultimately determine the electrophysiological properties of a neuron.
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Essential to the function of the long apical dendrite of the pyramidal neurons is the progressively
increasing density of hyperpolarization-activated cyclic nucleotide–gated (HCN) channels, proceeding
from proximal to distal segments [57]. Such a gradient critically contributes to the functional
distinction between dendritic compartments. Although Reln signaling specifies this gradient [58],
17β-estradiol, which stimulates Reln expression, promoted the enrichment of HCN1 in the distal
dendritic compartment of CA1 neurons without the intervention of Reln [59]. The evidence that Reln
was involved in the trafficking and targeting of ion channels in cortical and hippocampal neurons
suggested that their intrinsic electrophysiological properties could indeed be different in the Reeler
mouse. However, an early study by Bliss and Chung [60] demonstrated that, despite the layering
derangement, the basic synaptic organization of the hippocampus was largely unchanged in mutants.
More recently, Silva et al. [61] carried out an accurate survey dealing with the intrinsic
electrophysiological properties of cortical neurons in Reeler mice. These authors showed that the firing
pattern and synaptic responses of the pyramidal neurons were normal, but with an inverted radial
distribution. Notably, these authors concluded that, although mispositioned, neurons maintained the
membrane properties appropriate to their function.
The apparent discrepancy between the data demonstrating the role of Reln in the modulation of
ion channels and the relative lack of anomalies in the intrinsic properties of cortical neurons in mutant
mice might have several explanations. Other factors, such as neuronal activity [62] could be more
effective than Reln for the modulation of membrane channel targeting. Furthermore, the complex
machinery of the long apical dendrite is required when layer 5 neurons settle appropriately but
might be useless for the same neurons displaced to more superficial cortical layers. Finally, future
investigations based on refined electrophysiological techniques, such as direct dendritic recordings,
will help to establish if indeed the cortical neurons in Reeler mice display subtler changes of their
firing/intrinsic properties that those so far ascertained.
Reln signaling is also able to modulate key molecules of the cascade leading to synaptic plasticity,
such as the NMDA receptors [63,64]. Therefore, several studies concentrated on the changes of synaptic
plasticity in Reeler mutants. Ishida et al. [65] reported that the induction of long-term potentiation
(LTP) was impaired in the CA1 region of the hippocampus, claiming that the malpositioning of some
neuronal populations could account for such an alteration. On the other hand, both the overexpression
of Reln in transgenic mice [66] and Reln supplementation strongly increased LTP [67]. Later, a defective
LTP was observed in the hippocampus of vldr-deficient mice, but slice perfusion with Reln was able to
enhance LTP in CA1 [68].
Most cortical neurons are spiny, glutamatergic pyramidal cells, whose migratory path during
prenatal development follows an inside-out radial pattern from the ventricular zone to the final
position [69]. Reln signaling is essential for the localization of pyramidal neurons to appropriate
cortical layers, as reviewed in [70]. Consequently, the lack of Reln caused a disruption of the layered
cortical organization, including abnormal positioning [71,72], as well as an increased percentage of
inverted pyramidal cells [73,74] (Figure 2C,D).
Inhibitory GABAergic interneurons represent a minority population within the neocortex. Yet, their
morphological, neurochemical and functional diversity likely plays a key role for the cortical function,
see e.g., [75]. Unlike pyramidal neurons, interneurons originate in the ganglionic eminence of the ventral
telencephalon and follow a tangential migratory path to the cortex [69]. While the malpositioning
of the pyramidal neurons in Reeler mice is evident, it is not clear if the Reln signaling cascade also
affects the migration of the interneurons. An answer to this latter issue came from observations on
Reeler mutants crossed with mice expressing the green fluorescent protein (GFP) in inhibitory neurons.
Thus, the results of these observations confirmed that also the cortical interneurons displayed an
abnormal laminar position and morphology [76]. However, we still do not know whether interneurons’
ectopy directly depends from Reln signaling or is rather the consequence of the malpositioning of
principal pyramidal projection neurons. The debate on this issue is still open, as contradictory views
exist in the literature. Namely, while some observations [77,78] argue against a direct role of Reln,
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Hammond et al. [79] showed that only early-generated cortical interneurons were misplaced as a
consequence of the ectopy of the pyramidal neurons, whereas the correct layering of late-generated
interneurons seemed to be directly modulated by Reln signaling.
Other basic neurodevelopmental features, such as cortical [80] and cerebellar neurogenesis, seem
to be as well regulated by the glycoprotein. Consequently, the minicolumnar organization of the
cerebral neocortex appeared to be deeply affected by Reln deficiency [81] and some physiological
counterparts of cortical connectivity, such as trans-synaptic signal propagation, were also impaired [82].
However, the outcome of Reln deficiency on the microcircuitry sustaining the cortical machinery is
controversial and, surprisingly, the deep architectonic disorganization that follows the lack of the
protein occurs in the absence of dramatic functional anomalies. Both early and more recent studies
point out that the absence of Reln did not prevent the development of functionally appropriate cortical
connections and maps [31,83–86]. In addition, when studied at the fine-scale electron microscopic level,
the basic synaptic organization of misplaced cortical neurons was unchanged [87]. Therefore, although
the laminar organization is thought to be critical for cortical computation [88,89], evidences obtained
in Reeler mice led Guy and Staiger [90] to challenge the importance of cortical lamination, affirming
that “future studies directed toward understanding cortical functions should rather focus on circuits
specified by functional cell type composition than mere laminar location”.
Macroscopically, the cerebellum of the Reeler mouse is smaller than that of age-matched littermates
(Figure 2E,F); it is club-shaped with the main axis transverse to the mid plan of the body, and has an
almost completely smooth surface, with just a few superficial grooves [91]. The architecture of the
Reeler cerebellum is profoundly different from the normal pattern, firstly because of the impairment
in the complicated series of migrations made by neurons to reach their destination in the mature
organ. Trajectories of migrating neurons follow two opposite directions from the surface to the depth
of the cerebellum and the other way around, depending from the species, the type(s) of neurons
and the developmental stages (for details see e.g., [92]). Eventually, disturbances in the migration
of the cerebellar neurons make that Reeler mice display a cerebellum that retains several features
of immaturity.
The area of the cerebellar cortex in mutants was analyzed quantitatively during postnatal (P0–P25)
development and resulted to be reduced compared to age-matched controls [93]. Reduction in the
extension of the cortex was particularly evident in the molecular layer and the (internal) granular layer.
Physiologically, as the cerebellum matured, the molecular layer became more and more populated by
the parallel fibers, but, at P25, its increase in size was about one third in the mutants compared to reln+/+
mice [93]. Post-migratory granule cells, which are born in the temporary subpial external granular
layer, progressively populate the (internal) granular layer during normal cerebellar development.
This process was disturbed in Reeler, to the extent that, from P0 to P10, the granular layer of reln+/+ mice
increased about five-folds in size, but only 2.6-fold in reln−/−, where it was significantly reduced in size
to 0.62-fold that of normal mice after P10 [93]. In a different way from the cortex, the medullary body
was larger in the mutants than in wild-type mice. Its progressively increasing area mainly reflected
the ongoing myelination of the axons of the Purkinje neurons that abandon the cortex moving across
the white matter to reach the cerebellar nuclei, as well as the expansion of the incoming afferent and
departing efferent fiber systems. The mass of the medullary body augmented in relation to postnatal
age irrespectively of the lack of Reln (reln−/− 2.59, reln+/+ 1.93-fold), but, at P25, Reeler mice had a
larger medullary body than normal mice (1.88-fold) [93]. In brief, Reeler mice had a reduced cerebellar
cortex but a bigger medullary body than their reln+/+ littermates. The cerebellar hypoplasia was thus
a consequence of a reduction in cortical magnitude and cellularity and the latter, in turn, resulted
to be associated to measurable differences in the degree of cell proliferation and apoptosis, as well
as imbalances in the timing of postnatal cortical maturation [93]. The same study led to conclude
that density of proliferating cells was the most significant predictive factor to determine the cortical
cellularity in Reeler [93]. Therefore, beside the well-defined consequences onto neuronal migration,
the lack of Reln also caused a calculable deficit in neuronal expansion. Ultrastructurally, the cerebellar
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neurons underwent several different forms of programmed cell death during postnatal development
and the deficit of Reln affected the kind and grade of neuronal death [94].
Perhaps the most striking histological feature in mutants is the lack of alignment of the Purkinje
neurons to form a discrete intermediate layer in the cerebellar cortex (Figure 2G,H). Thus, in Reeler,
only about 5% of the Purkinje neurons were in a normal position, 10% were still inside the cortex but in
the granular layer, and the remaining 85% formed an internal cellular mass intermixed with the white
matter [95–97]. Ultrastructurally, in Reeler there was a reduction in the density of the contacts between
the Purkinje neurons and the parallel and climbing fibers, from P5 onward [98]. Functionally, both the
normally placed Purkinje neurons and those ectopically dislocated in the granular layer displayed
a 0–1 response to stimulation, indicating that, as in normal mice, they received a synaptic contact
by a single climbing fiber. The Purkinje neurons in the internal cellular mass, instead, showed
intensity-graded responses to electrical stimulation, as several climbing fibers provided them with a
convergent input [95], likely as a failure of physiological pruning to occur [99]. Neurochemically, there
were no obvious variations between normal mice and the mutants in the temporal expression of some
widely diffused neuronal and glial markers (NeuN, vimentin, calbindin, GFAP, Smi32, GAD67) during
postnatal development [93], but the Bergmann glia was misplaced in Reeler [100].
To conclude, the histological and electrophysiological observations in Reeler mutants suggest that
similar structural and functional alterations may also occur in LIS2 patients, particularly in relation
to the postnatal growth retardation, severe intellectual disability, and spasticity observed in affected
subjects (see also https://www.orpha.net/).
Lissencephaly 3
TUBA1A mutations [101,102] cause lissencephaly 3 (LIS3), another human condition that has
a mouse counterpart. TUBA1A chiefly occurs in cortical, hippocampal, cerebellar and brainstem
post-mitotic neurons, with expression falling soon after birth but persisting through adulthood [103].
The mouse phenotype consists, among others, in a failure of the cerebellar Purkinje neurons to migrate,
so that, similarly to Reeler, they remain entrapped into the medullary body, where they form a series
of streaks intermingled with the neurons of the cerebellar nuclei [104]. Several other mutations of
TUBA1A exist in humans. They give rise to a predominant phenotype of LCH, which also shows
irregularities of the corpus callosum and the basal ganglia/internal capsule [105].
3.1.2. Autosomal-Dominant Lateral Temporal Epilepsy and the Heterozygous Reeler Mouse
ADLTE, also referred to as autosomal dominant epilepsy with auditory features, partial epilepsy
with auditory aura or partial epilepsy with auditory features, is a genetic epileptic syndrome, clinically
showing typical focal seizures in response to specific sounds. ADLTE is genetically heterogeneous,
and mutations in the leucine-rich, glioma inactivated 1 gene (LGI1) account for fewer than 50% of
affected families. Very recent observations demonstrated that heterozygous RELN mutations give
rise to a classic ADLTE syndrome, clinically identical to that associated with mutations of LGI1.
Seven different heterozygous missense mutations in RELN were, in fact, described in some unrelated
families of Italian ancestry with familial temporal lobe epilepsy-7 (ETL7–OMIM #616436) [106].
Incidence was 17.5% over the total number of families studied that were specifically suffering by
lateral temporal lobe epilepsy [106]. By three-dimensional modeling, the same authors anticipated
that the outcomes of these mutations would be protein structural defects and misfolding. Some of
the affected individuals displayed a reduction up to 50% of their serum levels of the 310 kDa RELN
isoform in comparison to healthy subjects and thus, very likely, the mutations also resulted in a loss of
function. In a subsequent study on the same patients, 1.5 T MRI scans were not useful in detecting
structural anomalies of the brain [107]. Similarly, in a very recent study on an 18-year old ADLTE
patient, 3T MRI brain scans could not provide relevant information on indistinct grey-white matter
connections, voxel-based morphometry, and cortical thickness [108]. However, analysis of functional
connectivity with high-density electroencephalography (HdEEG) revealed greater local synchrony in
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the left temporal (middle temporal gyrus), left frontal (supplementary motor area, superior frontal
gyrus), and left parietal (gyrus angularis, gyrus supramarginalis) regions of the cerebral cortex and the
cingulate cortex (middle cingulate gyrus) as compared to normal subjects [108].
As the discovery of RELN mutations in ADLTE is a quite recent finding, there are, at present,
no observations on heterozygous Reeler mice focused to ascertain possible similarities with the human
phenotype. Like ADLTE patients, reln+/− mice display a 50% reduction of Reln in their serum.
Therefore, it would be interesting to investigate whether sound-triggered epileptic manifestations also
occur in these animals. A very recent study has demonstrated that optogenetic stimulation of the
parvalbumin (PV) immunoreactive GABAergic neurons of the mouse basal forebrain can modulate
the cortical topography of auditory steady-state responses [109]. As the regional distribution of
these neurons displayed relevant differences in reln+/− mice compared to wild-type animals [110,111],
any phenotypic alteration may be of interest to shed additional light onto human ADLTE. Finally, a very
latest report has provided proof of concept that HdEEG can be used to record electrical activity from
the mouse brain in a model of juvenile myoclonic epilepsy [112]. Therefore, one can envisage applying
such an approach to analyze the brain electrical pattern in reln+/− mice aiming to collect data for
translational comparison with ADLTE.
3.2. Human Conditions Caused byMutations of Genes of the Reln Intracellular Pathway and Their Mouse Correlates
In general, the brain phenotype of the human monogenetic conditions that are consequent to
mutations of the genes coding for the proteins of the RELN intracellular signaling pathway is similar
to that of the reln−/− mouse brain, except that, in certain cases, differently from Reeler, the human
cerebellum is normal at MRI and gross anatomical observation (Figure 1). We will briefly describe
these conditions below.
3.2.1. VLDLR-Associated Cerebellar Hypoplasia
VLDLR-associated cerebellar hypoplasia is an autosomal recessive genetic form of non-progressive
congenital ataxia [113]. The main clinical symptom of the condition is a predominantly truncal
ataxia with retarded ambulation, so that children either learn to walk after six years of age or never
walk without aid. Dysarthria, strabismus, moderate-to-profound intellectual disability, and seizures
are other features of the disorder. MRI findings comprise hypoplasia of the inferior portion of the
cerebellum, affecting both the vermis and the hemispheres; pachygyria of the cerebral hemispheres
with a negligibly but uniformly thickened cortex in the absence of a neat anteroposterior gradient,
reduction is size of the brainstem, particularly the pons. The condition is monogenic, and due to
mutations in VLDLR.
Vldlr only knock-out mice did not show the drastic brain phenotype that can be seen in double
knock-out mice devoid of vldlr and apoER2, which, instead, recapitulate in full the phenotypic alterations
of Reeler mutants or dab1 knock-out mice [21,114]. As Reln interacts with both Vldlr and ApoER2,
clear functional differences in how these two receptors transduce the glycoprotein signal have been
postulated [114]. That the interaction of Reln with Vldrl occurs with much lower affinity than with
ApoER2 [115] could explain the less severe phenotype of the vldlr knockout mice compared to Reeler.
Remarkably, alterations that in mouse followed the knocking-out of vldlr were particularly noticeable
in cerebellum and consisted in failure of the Purkinje neurons to form a well-defined monolayer
and reduction of their dendritic arbor [114]. They thus recall in full the human MRI phenotype of
VLDLR-associated cerebellar hypoplasia.
3.2.2. Spinocerebellar Ataxia Type 37
Spinocerebellar ataxia type 37 (SCA37) is a late onset syndrome that affects adults, with dysarthria,
slowly progressive gait and limb ataxia, severe dysmetria in the lower extremities, mild dysmetria in
the upper extremities, dysphagia, and abnormal ocular movements. In most cases, the first clinical
signs encompass tumbles, dysarthria, or stiffness followed by a typical cerebellar syndrome. The early
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presence of altered vertical eye movements is a characteristic clinical feature of SCA37 that foregoes
the symptoms of ataxia. The progression is slow and affected individuals usually become wheelchair
bound between ten and thirty-three years after the onset of the disease [116]. At MRI, there is an initial
atrophy of the vermis. Later, atrophy rapidly affects the entire cerebellum, without alterations of the
brainstem [117]. Molecular analysis has shown that an unstable repeat insertion in DAB1 is the cause
of the cerebellar degeneration and, on the basis of the genetic and phenotypic evidence, the mutation
has been proposed as the molecular basis for SCA37 [118].
Notably, the dab1 deficient mice that derived from a spontaneous mutation called Scrambler or
from gene knockout were phenotypically indistinguishable from the homozygous Reeler mice [119].
3.2.3. PAFAH1B1-Associated Lissencephaly/Subcortical Band Heterotopia
PAFAH1B1-associated lissencephaly/subcortical band heterotopia, also referred to as
LIS1-associated lissencephaly/subcortical band heterotopia, encompasses Miller–Dieker syndrome
(MDS), isolated lissencephaly sequence (ILS) and, infrequently, subcortical band heterotopia (SBH) [120].
MRI findings for lissencephaly are the absence or the abnormal broadening of cerebral gyri, and the
aberrant thickness of the cerebral cortex. Less frequently, it may be possible to observe an enlargement
of the lateral ventricles, mild hypoplasia of the corpus callosum and of the cerebellar vermis.
In PAFAH1B1-associated SBH, just beneath the cortex of the parietal and occipital lobes there are
subcortical bands of heterotopic gray matter separated from the superficial cerebral cortex by a thin
layer of white matter. Histologically, the cerebral cortex in LIS1-associated lissencephaly consists of
four layers: a poorly defined marginal zone, which, however, has a very high cell density; a superficial
neuronal layer with diffusely scattered neurons; a deeper neuronal layer with relatively sparse neurons;
and a deepest neuronal layer with neurons arranged in columns.
The architectural alterations of the human cerebral cortex and hippocampus can be somewhat
recapitulated in genetically engineered mice. For example, the overexpression of pafah1b1 disturbed
neuronal migration and layer formation in the developing cerebral cortex [121], whereas lis1 deficiency
in homozygous mice resulted in early embryonic death and in heterozygous mice led to a derangement
of the normal hippocampal organization with ectopy of the granule cells [122]. Of note, Lis1, the protein
encoded by Pafah1b, is part of the Pafah1b complex and binds, downstream of the Vldlr receptor,
to Dab1 that becomes phosphorylated in response to Reln [123].
3.3. Human Conditions Possibly Related to RELN Mutations and Their Mouse Correlates
3.3.1. Spinocerebellar Ataxia Type 7
Spinocerebellar ataxia type 7 (SCA7) is an autosomal-dominant neurodegenerative syndrome
that outcomes from polyglutamine expansion of ataxin 7 (ATXN7). Remarkably, although ATXN7 has
a widespread expression in SCA7 patients, the pathology primarily hits the cerebellum and the
retina [124]. A recently published paper suggested that RELN might be a formerly unidentified factor
accountable for the tissue specificity of SCA7 [125].
3.3.2. Autism and the Heterozygous Reeler Mouse
The disorders of the autistic spectrum (ASD), which are characterized by social, behavioral,
and language insufficiencies, comprise Asperger syndrome, autism, and pervasive developmental
disorder-not otherwise specified (PDD-NOS). Less than 20% of these disorders, acknowledged as
“syndromic autism”, derives from monogenetic diseases, most commonly fragile X syndrome and
tuberous sclerosis. The remaining 80% of ASD cases are classified as “non-syndromic autism” and are
widely investigated to find candidate genes that may contribute to pathology [126].
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Genetics
At present autism cannot be considered, strictly speaking, a genetic disease, as one or more
causative gene(s) has (have) not been found yet. The first gene association study implicating RELN
in autism dates to 2001 [127]. However, subsequent gene population surveys yielded contrasting
results [128–131]. Nonetheless, a more recent meta-analysis showed that at least one single nucleotide
polymorphism (SNP) in RELN could be significantly associated with the risk of autism [132].
Therefore, results of SNP analysis appear to be compatible with the idea that heterozygous mutations in
RELN may contribute to the onset of the disorder. Genetic studies on autism led to two main outcomes:
1. the more predominant existence of rare or de novo inherited mutations of a number of genes in
autistic patients; 2. the discovery of certain common gene variants that contribute to the risk of autism
but are also present, albeit at lower frequency, in the normal population [133]. When more than two
de novo mutations occur in a gene, the latter becomes a very likely causative candidate of a disorder.
There are four unique documented de novo mutations of RELN associated with autism [134–136],
thus implicating RELN as a possible cause of ASD. However, although nonsense mutations are more
frequent in autistic patients than in controls after whole-exome sequencing, there is not a striking
gross increase of de novo mutations in the former [135]. To study autism heritability, one can also
employ a different approach that distinguishes total narrow-sense heritability from that due to common
gene variants. By this method, it was concluded that narrow-sense heritability of autism is ∼52.4%,
and that the main contribution heritability was due to common gene variants, whereas rare de novo
mutations contribute only for about 2.6% of cases, but substantially influence individual liability to
the condition [137]. Thus, RELN may primarily have a role in the individual predisposition to manifest
autism rather than being one of the contributory causes of the disorder.
Further support for a RELN involvement in autism derived from the detection of reduced
expression of the RELN transcript and protein in autistic individuals. Decreased RELN levels were
apparent in the superior frontal cortex [10] and cerebellum of autistics as compared to controls [10,11,138].
In these areas, the levels of RELN mRNA were lower, as was the DAB1 transcript, whereas VLDLR
mRNA levels augmented.
Imaging
Imaging findings in autism have been recently reviewed [139]. Numerous observations join to
prove that there is an atypical development of the brain in autistic children. Early cross-sectional studies
demonstrated that the brain of these children had a higher volume than that of regularly developing
subjects. However, growth curves in the two groups eventually met at later childhood. More specifically,
in the 6–35-year interval, there was an initial period of brain overgrowth, and then growth slowed
down or even stopped during early and late infancy to which a phase of fast reduction of the brain
volume eventually followed [140]. Neuroimaging data also indicated that differences in the brain of
autistic people started to be detectable within the first two years after birth, before clinical symptoms
became obvious. There are conflicting views about the probability that an accelerated growth rate of
the brain in this postnatal window goes together with the occurrence of early neurodevelopmental
perturbations [139]. In relation to this, it is relevant that we still do not know when the initial
neuropathological signs of autism occur, also from the paucity of studies on autistic children during
the first year of life.
The mechanisms at the basis of the abnormal growth of the autistic brain are also unclear.
Although most imaging studies have focused onto the gray matter of the cerebral cortex, there are data
indicating that an increased amount of cerebrospinal fluid in the subarachnoid space [141] and/or a
greater volume of the white matter [142] occurred in parallel to the enlargement of the autistic brain.
As regarding the cerebral cortex, its surface, but not thickness, increased in the autistic brain [143].
To summarize, that an initial brain overgrowth may be a reliable biomarker for autism remains
highly questionable. Thus, it seems more profitable to focus onto regional brain structural differences
in a more effective search for new neuroanatomical findings of clinical relevance [139].
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Before entering the description of regional MRI investigations in autism, it is important to stress
that, at present, there are no specific and/or causative objective findings for the condition, but, instead,
the very same regions altered in autism may be interested in other psychiatric conditions.
The individual constituents of the neural circuitries causal of ASD are well defined. They include
regions of the fronto-temporal, fronto-parietal, and dorsolateral prefrontal cortex (PFC); parts of the
limbic system; the fronto-striatal circuitry, and the cerebellum. Neuroimaging studies on these regions
have employed different approaches such as the definition of a region-of-interest (ROI), voxel- or
vertex-vise methods. Traditional ROI studies have reported atypical findings in brain areas that
participate to social cognition such as the medial PFC, the anterior cingulate cortex (ACC), the inferior
frontal cortex, the superior temporal sulcus, the amygdala, and the anterior insula.
The cerebellum was larger than in controls in several MRI studies on autistic patients older than
three years [144], but not in younger children [143]. Differently from the cerebellum, the size of the
vermis was smaller [145–147] or larger [146] or did not display any relevant difference [147], and such
discrepancies possibly depend from the different clinical presentations of the condition [147,148]. It is
also unclear whether there are differences in size of individual vermal lobules, as claimed by some
authors [145], but not others [147]. Similarly, there were no differences between cerebellar hemispheres
in one study [147], whereas another group has found the hemispheric size as the only significant
structural dissimilarity between verbal and nonverbal subjects [149].
The still fuzzy picture emerging from the imaging studies onto the autistic brain makes it very
difficult to compare the human and mouse data in the search for common biomarkers. To our
knowledge, there are only two MRI studies on the brain of the heterozygous Reeler mouse. In the
first, Badea and co-worker [29] reported that the total volume of the brain, the ventricular volume
and the hippocampal volume correspondingly raised of about 6%, 82%, and 7% compared to normal
control mice. However, after statistical analysis, they showed that these volumes were like those
of reln+/+ normal mice. They also measured the areas of different parts of the brain in comparison
with wild-type mice and found no differences in hippocampus and cerebellum, but an enlargement
of the lateral ventricles. A more recent paper confirmed the ventricular enlargement, but found a
reduction of the cerebellar volume, whereas the volume of the motor cortex as well as its thickness was
unchanged [150]. Therefore, given the paucity of data in mouse and the still unclear MRI pattern in
human autistic subjects, one can only conclude that, at present, the cerebellum could be a part of the
brain deserving further imaging investigations for translational purposes.
Histopathology
A series of histological alterations of the whole brain occur in the autistic brain. In the first
histological surveys, the only cortical area showing qualitative structural abnormalities was the ACC
that, in autistic patients, lacked architectural refinement and had only a coarse lamination [151].
However, in the following decades substantial amounts of data have been collected and the list of
cerebral structures displaying histopathological changes in ASD has grown substantially to include a
series of cortical regions, the amygdala, the cerebellum and the brainstem, see e.g., [152,153]. Below we
will briefly summarize the most significant histopathological findings in human patients and compare
them to those in the heterozygous Reeler mouse. However, the interpretation of both human and mouse
finding needs often much caution, because not all studies used sound quantitative approaches and/or
proper stereological procedures.
a) Changes Affecting the Whole Brain
The diffuse alterations observed in the brains of autistic subjects at postmortem included cortical
dysplasia and neuronal heterotopia, with the formation of aggregates of neuronal cell bodies in
anomalous positions [154]. Other alterations, i.e., differences in size of the neuronal nucleus and
perikaryon, occurred at the cytological level. These differences started being evident in young
children and became more apparent in adults, but then tended to re-equilibrate with time [155].
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Remarkably, there might be some compensations between different areas, as in some parts of the brain
neurons were bigger, but smaller in others.
In the autistic brain there was also an increase of the neuropil extension in certain but not all
cortical areas that have been investigated so far [156]. It is unclear which neuropil component(s)
is (are) responsible of these volumetric variations. Fewer dendrites were, in fact, immunostained
for microtubule-associated protein 2 (MAP2) in the PFC [157] and a reduction of dendritic spines
was reported in hippocampus [158], but other studies reached completely opposite conclusions after
examination of the pyramidal neurons from layers 2 and 5 in the frontal, temporal, and parietal
cortex [159]. The issue of dendrite and dendritic spines density is quite important in the general
framework of this discussion, because these parameters have been widely investigated, primarily
aiming to validate the heterozygous Reeler mouse as a translational model.
Alterations in neuronal differentiation and migration may also occur in the autistic nervous system
and, thus, the consequences of a dysregulation of these processes may be at the basis of whole brain
changes in autism [154]. In spite of this, there are only a few investigations on the expression of RELN
in the brain of autistic patients and, after quantitative analysis, there was no alteration in the density of
layer 1 RELN+ neurons in the superior temporal lobe of the autistic brain, although these neurons
represent about 70% of the total layer 1 population [160].
b) Brain Regional Changes
Forebrain
Most of the histopathological observations on the brain of autistic patients focused on the cerebral
cortex and hippocampus and, broadly speaking, alterations were almost exclusively restricted to
neurons. The parameters considered have been size, number, and density of the different neuronal
populations, often in relation to the cortical layers or the hippocampal subfields. A point of attention in
considering these studies is that, in several cases, comparative brain volume evaluations between autistic
patients and controls are missing, while they are, instead, essential to settle whether modifications in
cell density reflect true differences in total cell counts.
Cerebral Cortex
The autistic pathology affects several regions of the cerebral cortex.
The PFC, which plays a major role in cognitive control, displayed a general overgrowth with
an increase in the number of neurons, whereas glial cells were apparently unaffected. Among the
GABAergic interneurons, there was a numerical increase of the PV-immunoreactive chandelier neurons,
whereas the calbindin- and calretinin-expressing neurons were unaltered [153,161–163]. However, after
qRT-PCR, the levels of the RELN and GAD67 mRNAs diminished in the post-mortem PFC from autistic
patients in comparison to healthy controls [164].
In the inferior frontal cortex, changes affected the small-sized pyramidal neurons that did not
display numerical alterations but were of smaller size [163].
The fusiform gyrus, which intervenes in facial recognition and social interactions, had a reduced
neuronal density in layer 3, whereas neurons in layers 2, 5, and 6 were less numerous, being also
smaller in layers 5 and 6 [165], but these alterations were not confirmed in [166].
In the frontoinsular cortex and ACC, both intervening in emotional regulation and self and
others awareness, lamination was rudimental. In the former, von Economo neurons (VENs) of layer
5 increased in number [167–169], whereas in ACC neuronal density augmented in layers 1–2 of area
24a of the left hemisphere but diminished in layers 5–6 of area 24c; size, instead, diminished in all
layers of area 24b [151,170].
The anterior midcingulate cortex also displayed a numerical increase of VENs, as well as of the
pyramidal neurons of layer 5 that, however, were of smaller size [171].
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Lastly, the entorhinal cortex, which has a role in memory, navigation and perception of time,
displayed characteristic terminal swellings, referred to as spheroids [172] that were also observed in all
hippocampal subfields (see below).
Another issue of interest is the possibility that there are alterations in the minicolumnar
organization of the cerebral cortex in early age onset autism [156], as it might be the case in Reeler
mice. Specifically, it appeared that minicolumns were smaller, more numerous and with lower
neuronal density in several cortical areas of autistic (and Asperger’s syndrome) patients, although
these observations still need to be confirmed in full [156]. Under this perspective, it may be useful to
here recall some of the results on the localization of the neural cell adhesion molecule 2 (NCAM2) in the
Reeler mouse because the molecule has also been proposed as a predisposition gene for the development
of autism [173]. In mutants, NCAM2 immunopositive and negative patches formed a mosaic filled
with dendritic aggregates originating from two different populations of neurons in a fashion suggestive
of a minicolumnar organization [174,175]. However, one must consider these findings with much
caution, as that minicolumns are indeed the fundamental modular units of neocortical organization is
currently still a matter of debate, see e.g., [176] for review.
Whereas the human cerebral cortex has been widely investigated in autism, investigations on the
cerebral cortex of the heterozygous Reeler mouse have been relatively few but reported a reduction
in the levels of GAD67 [53,177] like that observed in humans. Since the studies on hippocampus led
to highly comparable results in the two species, it would be of importance to undertake rigorous
investigations on the number and density of the cortical neurons in reln+/− mice, with attention
to the different neurochemical populations of inhibitory interneurons. The results of these studies
will be relevant, from one side, to validate the mouse model and, from the other, to confirm some
numerical observations in humans that, as mentioned at beginning of this section, need validation
using approaches more reliable than those often employed at histopathology.
Hippocampus and Amygdala
In humans, beside the widespread occurrence of spheroids, other general changes in
hippocampus [151,158,172,178,179] consisted in a reduction of neuronal size and dendritic arbors,
and these smaller neurons appeared to be more densely packed. There were also a series of specific
modifications affecting the excitatory pyramidal neurons that were more numerous in CA1, but less
abundant in all other adjacent hippocampal regions. The GABAergic inhibitory interneurons, instead,
displayed a higher density, specifically the calbindin-immunoreactive neurons in the dentate gyrus,
the parvalbumin-immunoreactive neurons in CA1 and CA3, and the calretinin-immunoreactive
neurons in CA1 [151,158,172,178,179].
In the heterozygous Reeler mouse the hippocampus displayed reduced levels of GAD67, [53,177]
that could be somewhat restored after stereotaxic injections of Reln [67,180]. These experiments
indicated the existence of a causal link between the decrease in GAD67 expression and Reln
haplodeficiency. In keeping with such a possibility, Reln supplementation could, at least partly,
reverse such a decrease. Other experiments, in line with this interpretation, have confirmed that the
decrease in the levels of GAD67 in heterozygous mice can be overturned, e.g., after administration of
nicotine, which reduces the GAD67 promoter methylation and increases its transcription [177].
In heterozygous mice, pyramidal neurons displayed a reduction in the average length and width
of their apical and basal dendritic spines [52], consistent with the decrease in the spread of the
dendritic arbor of the same population of neurons in humans. Additionally, Reln supplementation was
effective in promoting a full (apical) or partial (basal shaft) spine recovery [180]. These morphological
observations are in line with a previous report showing that, in the forebrain, spines were hypertrophic
in mice conditionally overexpressing Reln [66]. At electrophysiological recordings CA1 pyramidal
neurons displayed reduced spontaneous inhibitory postsynaptic currents [181], an observation that
was fully coherent with the reduction of the inhibitory input from the GABAergic interneurons
observed histologically.
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Synaptic plasticity is fundamental for hippocampal function. In CA1 of heterozygous mice, LTP
was impaired [182] as well as long-term depression (LTD) [181], which returned to normal levels after
the administration of Reln [180]. Additionally, in reln+/− and reln−/− mice, post tetanic potentiation
(PTP), a form of short-term plasticity that depends on neurotransmitter release, was reduced in
CA1 [180,183] and could be reversed by Reln [180].
Collectively these data indicate that the experimental administration of the glycoprotein was
able to reverse the morphological, neurochemical, and physiological hippocampal deficits consequent
to a reduction of brain Reln. Translationally, they are very important because they offer some cues
for further investigations onto the autistic brain. It would be of interest to map the post-mortem
distribution of hippocampal RELN in patients compared to healthy controls, to ascertain whether the
pattern of immunoreactivity will be consistent between humans and mice.
In the autistic patients, several studies reported that the amygdala, which is involved in emotional
learning, increased in size and displayed an augmented density of neurons within the medial, central,
and cortical nuclei [151,184–187]. Neurons were, however, less numerous, although numerical
variations could be age dependent. To our knowledge, Boyle et al have investigated in detail the
amygdala of the homozygous Reeler mouse with a marker-based phenotypic approach [188], but there
are no data on heterozygous mice.
Cerebellum
Analysis of cerebellar alterations in autism has attracted many efforts of the basic researchers and
clinicians. The most consistent anatomic findings in autistic patients were a reduction in size of certain
lobules of the cerebellar vermis (but see 3.3.2b Imaging) and a decrease in the number [186,189–192] and
size [193,194] of the Purkinje neurons. The inhibitory GABAergic basket and stellate interneurons that
connect with these neurons did not show quantitative differences compared to normal cerebella [195].
This observation is indicative of a late developmental death of the Purkinje neurons, as they differentiate
well before the interneurons. In addition to structural observations, Western blots demonstrated a
reduction of about 40% in the level of expression of RELN in autistic patients related to age and sex
corresponding controls [11]. Quantitative RT-PCR also showed a drop of RELN and GAD67 mRNAs
in the post-mortem autistic brain [164].
Notably many of the histological alterations in the human autistic cerebellum are like those
described in reln+/− mice. These animals displayed a progressive loss of Purkinje neurons already
during the first weeks of life [35], and inferior numbers of these cells were observed in adult subjects
as well [196]. Human MRI studies did not allow, at present, to ascertain whether the cerebellar vermis
is hit by the pathology in its entirety or, rather, only at specific lobuli. Therefore, our group has, at first,
focused its attention on five different lobules, which receive diverse types of afferent functional inputs,
to analyze the number and topological organization of the Purkinje neurons in reln+/+ and reln+/− adult
mice of both sexes [197]. We have thus shown that the Purkinje neurons: 1. Displayed a lower density
in reln+/− males (14.37%) and reln+/− females (17.73%) compared to reln+/+ males; 2. Were larger in
reln+/− males than in the other phenotypes under study, and smaller in females (regardless of the reln
genetic background) than in reln+/+ males; 3. Were more messily arranged along the YZ axis of the
vermis in reln+/− males than in reln+/+ males and, except in central lobule, reln+/− females.
Very recently, as many observations have associated a number of synapse-related genes in the
genesis of autism and other neuropsychiatric conditions [198,199], we have examined the expression
of synaptophysin 1 (SYP1) and contactin 6 (CNTN6) in the vermis of reln+/− and reln+/+ adult mice of
both genders [200].
SYP1 is a pre-synaptic marker and CNTN6 is a marker of the synapses made by the parallel
fibers onto the Purkinje neurons’ dendrites. Notably, there is evidence, although still to be validated
in full, that SYP1 is involved in the structural alterations of the autistic synapses [189,201], and very
recent observations have shown that copy number variations [202] or a truncating variant [203] of
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CNTN6 are found in autistic patients. In addition, CNTN6 mutations may be a risk factor for several
neurodevelopmental and neuropsychiatric disorders [150,199,204].
In line with these human studies, we have demonstrated that reln+/− mouse males displayed a
statistically significant drop of 11.89% in SYP1 compared to sex-matched normal animals, whereas
no modifications were detected comparing reln+/+ and reln+/− females [200]. In reln+/− male and
female mice, reductions in SYP1 levels were particularly evident in the molecular layer, whereas in
heterozygous mice of both sexes a reduction in CNTN6 occurred in all the three cortical layers of the
vermis. In addition, alterations in the levels of expression of SYP1 in the molecular layer of male reln+/−
mice ensued across all lobules except lobule VII, but they were limited to lobule II for the granular
layer and lobule VII for the Purkinje cell layer.
Thus, the widespread reduction of SYP1 and of CNTN6 in the molecular layer of reln+/− male
mice well matched with the autistic phenotype in humans [150].
In the vermis (and the whole cerebellum), there is proof for a topographic segregation of the
areas controlling motion versus those connected to cognitive and affective functions, and the diverse
lobules are coupled with precise zones of the brain and spinal cord [205]. The CNS areas that handle
sensorimotor inputs are directly or indirectly connected with the anterior lobe (lobules I–V of the
vermis), lobule VIII, and, to a lesser grade, with lobule VI; on the contrary, cortical association areas
that collect non-motor responses are linked to lobules VI and VII. Existing clinical data indicate that
the vermis is the chief target of the limbic system, and physiological and behavioral observations
implicate the vermis in the regulation of emotions [206]. Therefore, the neurochemical modifications
of the cerebellar cortex in heterozygous mice are fully in line with the possibility that the social
and communication aberrations typical of autism rest on anomalies of the limbic system and its
connections [207,208].
At post-mortem, a numerical reduction of the Purkinje neurons in the posterior cerebellum was
long ago described in autistic subjects [184,209], but it did not appear to disturb the vermis [189].
Hypoplasia in lobules VI and VII was initially detected in vivo using MRI [145], but subsequent
observations proved the existence of two distinct autistic subtypes related to vermian hypoplasia
or hyperplasia [146]. A systematic review and meta-analysis of the accounts of structural MRI
has then established that the reduction in size of lobules VI–X (i.e., the lobules included in
the posterior cerebellum) showed a remarkable heterogeneity that associated to differences in
time of life and intelligence quotient (IQ) merely in lobules VI–VII [210]. Other observations
showed that the posterior/inferior vermis, i.e., lobules VII, VIIIb (left), and IX, was more prone
to pathological deviations [211], with a decrease of the gray matter after quantitative MRI [190,212,213].
Therefore, it appears that the cerebellar phenotype of the heterozygous Reeler mouse is fully compatible
with that in humans and that a deeper structural and neurochemical characterization may be useful to
direct the discovery of new biomarkers of translational interest.
3.3.3. Schizophrenia and the Heterozygous Reeler Mouse
Schizophrenia is a ruinous psychiatric condition that affects about 1% of the population. Its main
clinical symptoms are hallucinations, delusions, and cognitive disturbances. These symptoms
derive from brain dysfunctions that derive from genetic and environmental factors [214].
However, schizophrenia is not strictly a genetic disease, although gene deletions, duplications,
and variations may be risk factors for the disorder. At present, the gene(s) that could be involved
in the pathology remain elusive for the most (see OMIM #181500), but a microdeletion in a region
of chromosome 22, called 22q11, was recently established to be involved in a small percentage of
cases [215].
Genetic studies have shown a link between RELN and schizophrenia [216] and, over the past ten
years, many SNPs in the RELN gene loci occurred in parallel with the beginning and/or severity of the
clinical signs [217], but results still are under debate and need further verification [218]. One should
perhaps emphasize that observations on gene expression have converged to show that the genes
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implicated in schizophrenia are more highly expressed during fetal than postnatal life [219], thus
making more difficult to ascertain their true role in the etiology of the condition.
Imaging
Structural MRI findings in schizophrenia have been recently reviewed [220]. There is enough
information to propose that the condition is associated with a continuing development of gray matter
aberrations, chiefly throughout the first stages of the disease. Reduction of the depth of the cerebral
cortex in the superior temporal and inferior frontal regions was reported in individuals that later
became psychotic. In patients with first episode psychosis, there was, instead, a reduction in the
thickness of the superior and inferior frontal cortex, and in the volume of the thalamus. In chronic
schizophrenia, the gray matter decreased further in the frontal and temporal areas, cingulate cortices,
and thalamus, particularly in patients with unfortunate outcomes. Structural modifications of the
white matter occurred only in a small number of longitudinal studies.
As the human phenotype is still very far from clear, it is not surprising that the few MRI
observations in Reeler mice are still insufficient to draw any definitive consideration of translational
relevance (for MRI data on Reeler see 3.3.2 Imaging).
Histopathology
Although gross structural alterations of the brain were lacking, subtle pathological changes in
specific populations of neurons and in cell-to-cell communication occurred in schizophrenic patients,
see [221] for a recent review. Histopathology mainly consisted in modifications of the number and
density of neurons at the level of the whole brain and/or specific neuronal subpopulations, and in
morphological and neurochemical alterations of these neurons.
a) Cerebral Cortex
As discussed above for autism, the most widely investigated area of the brain has been the PFC
that, in general terms, displayed an increased neuronal density and an altered neuroplasticity with
age-related differences between normal and schizophrenic subjects. More specifically, a statistical
meta-analysis of thirty papers published between 1993 and 2012, concluded that the density of cortical
neurons increased with age irrespective of the condition, but the rate of accretion was much slower in
the schizophrenics [222]. However, other cortical areas, such as e.g., the dorsal ACC, displayed no
changes in neuronal and glial densities after stereological analysis [223].
The above-mentioned meta-analysis [222] has also taken into consideration the density of
inhibitory neurons after immunolabeling with GAD67, PV, or calbindin, and found that it was greater
in schizophrenic patients compared to controls before the age of 40, but lower thereafter.
Notably, both Reln and GAD67 mRNAs were downregulated in the PFC of schizophrenic subjects
with no relation to neuronal damage [224]. In keeping with these observations, it appeared that in the
PFC there was a vulnerability of the inhibitory circuits, with markers of the inhibitory interneurons
showing some of the more consistent alterations [225]. More precisely, these alterations consisted
in a reduction in the levels of the GAD67 mRNA and protein in subsets of GABAergic basket cells
containing PV [222,226,227] or cholecystokinin (CCK) [226]. Notably, these two populations of basket
cells are responsible of the inhibition of the pyramidal neurons giving rise, respectively, to the cortical
θ and γ oscillations altered in schizophrenia. In addition, the pyramidal neurons targeted by the PV+
basket cells expressed lower levels of the GABAA receptor α1 [226].
It is also interesting that the levels of RELN and GAD67 mRNAs in microdissected GABAergic
neurons of PFC layer 1 were lower in schizophrenics, but unchanged in layer 5 of the same patients [228].
In addition, in the dorsolateral division of the PFC, the GABAergic chandelier neurons targeting
the axon initial segment of the pyramidal neurons displayed remarkable neurochemical alterations.
These changes were particularly evident in layers 2/3, where immunoreactivity for the GABA membrane
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transporter GAT1 diminished, in parallel with an increase of the GABAA receptor α2 subunit in the
axons of their target pyramidal neurons [229].
Occurrence of dendritic spine pathology was another prominent feature of the schizophrenic
human brain [230,231]. Spine loss mainly affected the smaller spines of the pyramidal neurons in
layer 3 of the neocortex and arose during development, possibly because of altered mechanisms of
generation, pruning, and/or upkeep [230].
As already mentioned in the section dedicated to autism, investigations on the cerebral cortex
of the heterozygous Reeler reported a reduction in the levels of GAD67 [53,177], in full accordance
with the human studies. A study carried out on mice whose mothers were stressed during pregnancy
showed that the downregulation of Reln and GAD67 was associated with a hypermethylation of their
promoters [232], this being one the mechanisms in support for the contribution of an altered epigenetic
control in the down-regulation of RELN expression in schizophrenia, see [233] for review.
b) Hippocampus
The human hippocampal pathology in schizophrenia is by far less clear than in the cortex.
Some initial studies have, in fact, reported a decrease in area or overall volume of the hippocampus,
or in the number, size, and density of neurons, as well as a disarray of the pyramidal cells, with greatest
differences affecting the pyramidal cell density in left CA4; however, several other subsequent surveys
were negative, see [234] for review. In any case, hippocampal alterations in schizophrenics are not
specific, as they display several common traits with those in autism.
We have previously discussed the histological changes in the hippocampus of the heterozygous
Reeler mice in relation to autism. These modifications recall, in toto or in part, those in schizophrenia.
Additional information detailed, in individual hippocampal layers, the decrease of neuronal GAD67 in
CA1, CA2 and dentate gyrus, and the reduction of PV immunoreactive interneurons in CA1 and CA2,
in the perspective to validate these mice as a model of schizophrenia [111]. In translational terms,
the aforementioned impairment of LTP in heterozygous mice [182] is of interest, as it also occurs in
schizophrenic patients [235].
c) Cerebellum
In the cerebellum of schizophrenic patients, there was a loss of distal and terminal dendritic
branches and a decrease in density of the dendritic spines of the Purkinje neurons [236]. Again, these
histological alterations are not specific for the condition, being evident also in autism. In addition to
such changes, in the schizophrenic cerebellum there were altered levels of expression of the general
presynaptic marker SYP1, of complexin II, a marker of the excitatory synapses, but not of complexin
I that, instead, labels the inhibitory synapses [237]. Thus, some of the structural changes described
in the heterozygous Reeler mouse in relation to autism also in cerebellum recollected the human
schizophrenic phenotype.
4. Does the Behavior of Heterozygous Reeler Mice Recall the Human Conditions Related to RELN?
The recapitulation of the behavioral modifications typical of human autism, schizophrenia,
or epilepsy in heterozygous Reeler mice still is a subject of debate. The dissimilar outcome of behavioral
experiments performed in different laboratories is not surprising, because neuropsychiatric behaviors
in humans primarily regard social interaction, communication, and restricted interest, and these
behaviors are, obviously, very difficult to measure objectively in mice [238].
It is perhaps worth mentioning here that most of our knowledge on the effects of Reln in the
cognitive or behavioral field derives from work on mouse hippocampus. This is not surprising as
this part of the brain, as discussed previously, has been the primary focus of numerous investigations
also in human patients affected by neuropsychiatric disturbs. Several behaviors comparable to those
observed in these human disturbs also occur in reln+/− mice [239–241], as well as the deficits in
reversal learning after visual discrimination tasks that were hypothesized to follow a diminished visual
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attention [240]. In addition, testing reln+/− mice for anxiety-related behavior, motor impulsivity and
morphine-induced analgesia yielded a different behavioral profile from that of wild-type littermates
in that they displayed, starting form adolescence, a decreased inhibition and emotionality. To these
modifications, a small increase of impulsive behavior and different pain thresholds also occurred in
adult mice [242]. Heterozygous mice were also tested in a complex series of PPI protocols (unimodal and
cross-modal) to conclude that they exhibited a multifaceted configuration of changes in startle reactivity
and sensorimotor gating, with both resemblances to and dissimilarities from schizophrenia [243].
At least partly in line with these latter observations, other studies failed, incompletely or in full,
to validate the behavioral analogies between neuropsychiatric patients and reln+/− mice [181,244–248].
For example, Salinger and co-workers were unsuccessful to find differences between reln+/− and reln+/+
mice after testing gait, emotionality, social aggression, spatial working memory, novel-object detection,
fear conditioning, and sensorimotor reflex modulation [244]. In another survey [246], heterozygous
Reeler mice were evaluated for cognitive plasticity in an instrumental reversal learning task, impulsivity
in an inhibitory control task, attentional function in a three-choice serial reaction time task, and working
memory in a delayed matching-to-position task to conclude that there were no differences in comparison
to reln+/+ littermates in prefrontal-related cognitive trials. However, reln+/− mice were deficient in two
operant tasks. From these observations, the authors concluded that heterozygous Reeler mice were not
a good model for the essential prefrontal-dependent cognitive shortfalls detected in schizophrenia,
although they could be useful to model learning deficits in a more general sense.
In another paper it was reported that heterozygous and wild-type mice displayed comparable
levels of general activity, coordination, thermal nociception, startle responses, anxiety-like behavior,
shock threshold; identical cued freezing behavior, and comparable spatial learning in Morris water
maze tasks, albeit a significant decrease in contextual fear conditioned learning was observed in reln+/−
mice only [181]. These authors have then hypothesized that the pharmacological administration of
Reln in heterozygous mice could restore the response to PPI. They were unable to find differences in
the acoustic startle reflex among treated and untreated animals, but Reln-treated reln+/− mice showed a
substantial increase in the percent inhibition to 78-, 86- and 90-dB pre-pulse [180].
One study has specifically focused onto the reln+/− mouse behavioral phenotype in young
(P50–70) and fully adult (older than P75) animals to conclude that they were not useful to model
schizophrenia [245]. An ample series of behavioral test was used (Irwin test; rotarod; spontaneous
locomotor activity; social behavior; light-dark transition; startle response and pre-pulse inhibition; hot
plate). Heterozygous mice were like their wild-type littermates at either age, though completely adult
male reln+/− mice were involved in social exploration for a longer time. In addition, performance on
the rotarod deteriorated with age.
Indeed, age appeared to be a further issue of complexity. In fact, adult reln+/− mice did not display
discernible changes in activity, motor coordination, anxiety, or environmental perception compared
to wild-type littermate controls. However, juvenile animals displayed not as much of anxiety- and
risk assessment-related behaviors in the elevated plus-maze [182,241]. In addition, in one of these
two studies it was demonstrated that young reln+/− mice had a hippocampal-dependent shortfall in
associative learning and impulsivity–anxiety-related behavior [182]. Additionally, one study, starting
from the clinical observations that reported the occurrence of vocal and motor anomalies in autistic
patients, has described that reln+/− mice had a general delay in the development of their repertoire of
neonatal vocal and motor behaviors [249].
Finally, one must consider that gender apparently influenced some behaviors, although very
few studies have focused on this issue. Among these studies, young heterozygous female mice were
described to be more active in the light/dark transition test than the heterozygous males that were,
instead, more aggressive than females during social interaction [241].
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5. Usefulness of the Reeler Mouse in Translational Studies: Concluding Remarks
The analysis of the literature discussed above requires one trying to draw some conclusions about
the true usefulness of the Reeler mouse in translational studies.
At first, it may perhaps be useful to remember that, as discussed, RELN is causative of LIS2 and a
small percentage of ADLTE, whereas only tentative associations up to now hold for the other conditions
here considered (see Figure 1 and Table 1).
Remarkably, both LIS2 and ADLTE are rare diseases. Very few cases of LIS2 (around ten) so far
come about in the literature (see OMIM #257320). Similarly, patients with lateral temporal epilepsy (LTE)
are only about 10% of all temporal epilepsies, and the real prevalence of ADLTE, which has been up
to now reported in Europe, USA, and Japan, is unknown, but it may account for about 19% of familial
idiopathic focal epilepsies [250,251]. When one considers the human conditions related to the Reln signaling
pathway, one still encounters a group of rare diseases. The actual frequency of VLDLR-associated cerebellar
hypoplasia is unknown, but initial reports regarded not more than twenty-five affected individuals in
Canada and USA [113,252], although the condition occurs worldwide, PAFAH1B1-associated lissencephaly
is very rare as the prevalence of classic lissencephaly ranges from 11.7 to 40 per million births [120]. To date,
sixty-six affected individuals and seven asymptomatic individuals with the ATTTC repeat insertion within
DAB1 have been reported in ten relatives from the south of the Iberian Peninsula, and no individuals
with SCA37 from other geographic areas have been described [116]. SCA7 has a prevalence of less than
1:100,000 and accounts for about 2% of all SCAs [253].
Therefore, one must deal with the paradox of the relatively little interest for translational studies
on the very conditions for which the Reeler mouse and/or mice with mutations of the genes of the Reln
pathway fully meet the criteria for construct and face validity. Thus, the homozygous Reeler mice
appear to be more interesting to the neurobiologist than to the clinician and their study will surely be
still rewarding in terms of our comprehension of neurodevelopment, as the model already helped to
establish that many functional and circuit features of cortical neurons are relatively independent from
positional cues and cortical lamination, e.g., [179].
Very differently, the prevalence of autism in the worldwide population is around 1% [254] and that of
schizophrenia is just below [221]. As the two conditions are very diffuse in the human population, there
is an obvious translational interest for the heterozygous Reeler mouse as a model for the two disorders.
However, such an interest is again paradoxical, as the validity of these mice to extract information about
the human pathologies remains dubious. The first explanation for this uncertainty lies, beyond any
doubt, in the substantial lack of construct validity, which is the direct consequence of the complex genetic
background of autism and schizophrenia. As regarding face validity, the present survey of the literature
clearly points out that there are several similarities but also dissimilarities between the human and the
mouse phenotypes. Among dissimilarities, one must consider the heterogeneity of results of the behavioral
experiments in mouse. Further complexity derives by the vast array of clinical symptoms in humans.
Structurally, most of the imaging and post-mortem findings in humans are not specific for each of the two
conditions. However, one must consider that both the human and mouse phenotype converges to indicate
the cerebral cortex, hippocampus, and cerebellum as the primary foci of the pathologies and the inhibitory
interneurons as major players in the context of the circuitry involved.
A serious drawback to a full validation of the heterozygous Reeler mouse as a model of autism
and/or schizophrenia lies in the observation that the alterations so far described in mouse are very
subtle in both structural, functional and neurochemical terms. The relatively low resolution of current
neuroimaging procedures, and the difficulty to obtain post-mortem samples amenable for neurochemical,
electrophysiological, and fine (ultra) structural analyses make it very difficult to establish whether
the alterations in heterozygous Reeler mice have a true biological significance that goes beyond mere
statistics [255,256]. In the affirmative, one could take advantage of these alterations to discover novel
biomarkers that will be helpful for an earlier and more precise diagnosis in the human practice.
Author Contributions: All authors contributed to write the manuscript.
J. Clin. Med. 2019, 8, 2088 23 of 36
Funding: The original research work carried out at the Department of Veterinary Sciences described in this paper
was funded by Local Grants of the University of Turin to LL and AM and FFABR 2017 from the Italian MIUR to
CC. AG was in receipt of a Local Grant of the Catholic University of the Sacred Heart, Milano.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
ACC anterior cingulate cortex
ADLTE autosomal-dominant lateral temporal epilepsy
ApoER2 apolipoprotein E2
ARX aristaless-related homeobox gene
ASD autism spectrum disorders
ATXN7 ataxin 7
CCK cholecystokinin
CNS central nervous system
CNTN6 contactin 6
DCX doublecortin
DTI diffusion tractography imaging
ETL7 temporal lobe epilepsy-7
GFP green fluorescent protein
HCN hyperpolarization-activated cyclic nucleotide–gated
HdEEG high-density electroencephalography
ILS isolated lissencephaly sequence
IQ intelligence quotient
LCH lissencephaly with cerebellar hypoplasia
LGI1 leucine-rich, glioma inactivated 1 gene
LIS1 lissencephaly 1
LIS2 lissencephaly 2
LIS3 lissencephaly 3
LTD long-term depression
LTE lateral temporal epilepsy
LTP long-term potentiation
MAP2 microtubule-associated protein 2
MDS Miller-Dieker syndrome
MEMRI manganese-enhanced MRI
NCAM2 neural cell adhesion molecule 2
PAFAH1B1 platelet-activating factor acetylhydrolase IB subunit α
PDD-NOS pervasive developmental disorder-not otherwise specified
PFC prefrontal cortex
PPI pre-pulse inhibition
PTP post tetanic potentiation
PV parvalbumin
RELN Reelin gene (human)
Reln Reelin gene (mouse)
RELN Reelin glycoprotein (human)
Reln Reelin glycoprotein (mouse)
ROI region-of-interest
SBH subcortical band heterotopia
SCA37 spinocerebellar ataxia type 37
SCA7 spinocerebellar ataxia type 7
SNP single nucleotide polymorphism
SYP1 synaptophysin 1
TUBA1A α tubulin 1A
VENs von Economo neurons
VLDLR very low-density lipoprotein receptor
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